Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dingell generic drug probe

Executive Summary

House Commerce/Oversight & Investigations Subcommittee plans to interview more than the 60 FDA employees it had initially targeted for questioning in its investigation into the agency's generic drug approval process. The subcommittee, chaired by Rep. Dingell (D-Mich.), expects to finish first round of interviews, including the 60 FDAers, during the week ending April 8. Dingell has said that the interviews are necessary due to the expansion of the generic drug approval inquiry launched last summer ("The Pink Sheet" March 20, p. 3).

You may also be interested in...



In Flood Of 2020 Sanitizer Launches, Unilever’s Suave Brand Tops US Category Sales

Unilever’s Suave brand led new sanitizer product sales in 2020, when hand sanitizers total sales grew 569%, according to IRI. Sales of rinseable hand-soap sales grew 64% and antiseptics 19%.

Turkish Medtechs Face The Constant Challenge Of Sailing In Stormy Seas

The pandemic has exacerbated the problems of the Turkish medical device industry, which was already struggling for survival and growth in a hostile policy environment. Local blood bag manufacturer Kansuk Laboratory talked to Medtech Insight about the difficulties it faces.

Pipeline Watch: Phase III Readouts For COVID-19, Dry Eye Disease, Uveal Melanoma

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

UsernamePublicRestriction

Register

PS015336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel